OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Operating Cash Flow

Last Annual Value

-51.83M

3-Year CAGR

-24%

5-Year CAGR

-23%

10-Year CAGR

-11%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Operating Cash Flow

OKUR · NASDAQ
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
-51.83M
N/AN/AN/A 
-27.75B
N/AN/AN/A
-51.78M
N/AN/AN/A
-82.50M
N/AN/AN/A
-18.81M
N/AN/AN/A
-4.99M
N/AN/AN/A
-33.07M
N/AN/AN/A
-82.34M
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47